NTLA Intellia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NTLA

Price (delayed)

$32.86

Market cap

$2.91B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.44

Enterprise value

$2.86B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The company's quick ratio rose by 29% YoY
The gross profit has grown by 17% YoY
The company's debt has surged by 76% YoY but it fell by 3% QoQ
Intellia Therapeutics's equity has increased by 25% YoY but it has decreased by 7% from the previous quarter
The net income has contracted by 13% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intelliatx.com/
Peers: OMGA

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
88.49M
Market cap
$2.91B
Enterprise value
$2.86B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
54.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.89
Earnings
Revenue
$53.04M
EBIT
-$453.44M
EBITDA
-$445.24M
Free cash flow
-$384.18M
Per share
EPS
-$5.44
Free cash flow per share
-$4.36
Book value per share
$12.54
Revenue per share
$0.6
TBVPS
$15.01
Balance sheet
Total assets
$1.32B
Total liabilities
$218.35M
Debt
$122.33M
Equity
$1.1B
Working capital
$839.76M
Liquidity
Debt to equity
0.11
Current ratio
9.41
Quick ratio
9.14
Net debt/EBITDA
0.11
Margins
EBITDA margin
-839.5%
Gross margin
100%
Net margin
-854.9%
Operating margin
-867.1%
Efficiency
Return on assets
-33.9%
Return on equity
-41.6%
Return on invested capital
-42.9%
Return on capital employed
-37.1%
Return on sales
-854.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
2.02%
1 week
-4.39%
1 month
-14.09%
1 year
-39.37%
YTD
-5.82%
QTD
-19.42%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$53.04M
Gross profit
$53.04M
Operating income
-$459.91M
Net income
-$453.44M
Gross margin
100%
Net margin
-854.9%
The gross profit has grown by 17% YoY
Intellia Therapeutics's revenue has increased by 17% YoY
The company's operating income fell by 16% YoY and by 8% QoQ
The net income has contracted by 13% YoY and by 5% from the previous quarter

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
2.62
P/S
54.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.89
The stock's P/B is 52% below its 5-year quarterly average of 5.3 and 22% below its last 4 quarters average of 3.3
Intellia Therapeutics's equity has increased by 25% YoY but it has decreased by 7% from the previous quarter
The price to sales (P/S) is 38% lower than the 5-year quarterly average of 86.4 and 19% lower than the last 4 quarters average of 65.8
Intellia Therapeutics's revenue has increased by 17% YoY

Efficiency

How efficient is Intellia Therapeutics business performance
Intellia Therapeutics's ROIC has decreased by 8% YoY
The ROS has contracted by 6% from the previous quarter but it has grown by 3.2% YoY
The ROA has contracted by 4.6% YoY
Intellia Therapeutics's ROE has decreased by 3.5% YoY

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
NTLA's current ratio is up by 30% year-on-year
The company's quick ratio rose by 29% YoY
The company's debt is 89% lower than its equity
The company's debt has surged by 76% YoY but it fell by 3% QoQ
The debt to equity has grown by 38% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.